Original Research| Volume 109, P175-182, March 2019

Download started.


Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial

Published:February 05, 2019DOI:


      • The addition of metronomic chemotherapy to bevacizumab (bev) during maintenance does not significantly improve PFS.
      • 5FU/bev is the standard maintenance following upfront FOLFOXIRI/bev.
      • The activity of FOLFOXIRI/bev is confirmed with 4 instead of 6 months duration.
      • Results among BRAF mutants are consistent with previous findings with FOLFOXIRI/bev.



      Alternating induction and maintenance phases is a common strategy in metastatic colorectal cancer (mCRC). Metronomic chemotherapy (metroCT) may represent a well-tolerated chemotherapy backbone for maximising bevacizumab effect during maintenance. The MOMA trial was designed to compare metroCT plus bevacizumab versus bevacizumab alone as maintenance following 4 months of induction with FOLFOXIRI plus bevacizumab.

      Patients and methods

      In this phase II study, patients with unresectable mCRC were randomised to receive up to 8 cycles of FOLFOXIRI plus bevacizumab, followed by bevacizumab (arm A) or the same regimen followed by bevacizumab plus metroCT (capecitabine 500 mg/three times per day and cyclophosphamide 50 mg/die, arm B) until disease progression. The primary end-point was progression-free survival (PFS). According to the Rubinstein and Korn's design, to detect a hazard ratio[HR] of 0.75 favouring arm B, with 1 sided-alpha and beta errors of 15% and 80%, 173 events and 222 patients were required.


      Between May 2012 and March 2015, 232 patients, mostly with RAS (65%) or BRAF (9%) mutant tumours, were randomised in 16 Italian centres.
      At a median follow-up of 47.8 months, 210 and 164 progression and death events were registered. The primary end-point was not met. Median PFS was 10.3 and 9.4 months in arm B and A, respectively (HR: 0.94 [70% confidence interval {CI}: 0.82–1.09], p = 0.680). No significant differences were reported in terms of overall survival (OS) (median OS arm B/A: 22.5/28 months; HR: 1.16 [95%CI: 0.99–1.37], p = 0.336).
      Response rate with FOLFOXIRI plus bevacizumab was 63% (arm B/A: 58%/68%). In the liver-limited subgroup, the secondary resection rate was 49% (arm B/A: 45%/55%).


      The addition of metroCT to maintenance with bevacizumab does not significantly improve PFS of mCRC patients. The activity of FOLFOXIRI plus bevacizumab is confirmed in a population with high prevalence of RAS/BRAF mutations treated with a 4-months induction.

      Trial registration


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Tournigand C.
        • Cervantes A.
        • Figer A.
        • Lledo G.
        • Flesch M.
        • Buyse M.
        • et al.
        OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.
        J Clin Oncol. 2006; 24: 394-400
        • Chibaudel B.
        • Maindrault-Goebel F.
        • Lledo G.
        • Mineur L.
        • André T.
        • Bennamoun M.
        • et al.
        Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study.
        J Clin Oncol. 2009; 27: 5727-5733
        • Labianca R.
        • Sobrero A.
        • Isa L.
        • Cortesi E.
        • Barni S.
        • Nicolella D.
        • et al.
        Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised “GISCAD” trial.
        Ann Oncol. 2011; 22: 1236-1242
        • Wasan H.
        • Meade A.M.
        • Adams R.
        • Wilson R.
        • Pugh C.
        • Fisher D.
        • et al.
        Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial.
        Lancet Oncol. 2014; 15: 631-639
        • Díaz-Rubio E.
        • Gómez-España A.
        • Massutí B.
        • Sastre J.
        • Abad A.
        • Valladares M.
        • et al.
        First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study.
        Oncol. 2012; 17: 15-25
      1. 499ophase ii study of first-line mfolfox plus cetuximab (c) for 8 cycles followed by mfolfox plus C or single agent (s/a) C as maintenance therapy in patients (p) with metastatic colorectal cancer (mcrc): the macro-2 trial (Spanish cooperative group for the treatment of digestive tumors [ttd]). - semantic scholar n.d./paper/499ophase-Ii-Study-of-First-line-Mfolfox-plus-(c)-8-Alfonso-Benavides/d707712235b217d6aceec227dd5499ab67a61a60 [Accessed 5 July 2018].

        • Simkens L.H.J.
        • van Tinteren H.
        • May A.
        • ten Tije A.J.
        • Creemers G.-J.M.
        • Loosveld O.J.L.
        • et al.
        Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
        Lancet. 2015; 385: 1843-1852
        • Koeberle D.
        • Betticher D.C.
        • von Moos R.
        • Dietrich D.
        • Brauchli P.
        • Baertschi D.
        • et al.
        Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06).
        Ann Oncol. 2015; 26: 709-714
        • Hegewisch-Becker S.
        • Graeven U.
        • Lerchenmüller C.A.
        • Killing B.
        • Depenbusch R.
        • Steffens C.-C.
        • et al.
        Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
        Lancet Oncol. 2015; 16: 1355-1369
        • Loupakis F.
        • Cremolini C.
        • Masi G.
        • Lonardi S.
        • Zagonel V.
        • Salvatore L.
        • et al.
        Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
        N Engl J Med. 2014; 371: 1609-1618
        • Bendell J.C.
        • Tan B.R.
        • Reeves J.A.
        • Xiong H.Q.
        • Laeufle R.
        • Byrtek M.
        • et al.
        STEAM: a randomized, open-label, phase 2 trial of sequential and concurrent FOLFOXIRI-bevacizumab (BEV) versus FOLFOX-BEV for the first-line (1L) treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC).
        J Clin Orthod. 2014; 32 (TPS3652–TPS3652)
        • Satake H.
        • Sunakawa Y.
        • Miyamoto Y.
        • Nakamura M.
        • Nakayama H.
        • Shiozawa M.
        • et al.
        A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11.
        Oncotarget. 2018; 9: 18811-18820
      2. “CHARTA”: FOLFOX/Bevacizumab vs. FOLFOXIRI/Bevacizumab in advanced colorectal cancer—Final results, prognostic and potentially predictive factors from the randomized Phase II trial of the AIO. J Clin Oncol. Vol 35, No 15_suppl n.d. [Accessed 2 July 2018]..

        • Bocci G.
        • Francia G.
        • Man S.
        • Lawler J.
        • Kerbel R.S.
        Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy.
        Proc Natl Acad Sci USA. 2003; 100: 12917-12922
        • Kerbel R.S.
        • Kamen B.A.
        The anti-angiogenic basis of metronomic chemotherapy.
        Nat Rev Canc. 2004; 4: 423-436
        • Bazzola L.
        • Foroni C.
        • Andreis D.
        • Zanoni V.
        • R Cappelletti M.
        • Allevi G.
        • et al.
        Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer.
        Br J Canc. 2015; 112: 52-60
        • Klement G.
        • Baruchel S.
        • Rak J.
        • Man S.
        • Clark K.
        • Hicklin D.J.
        • et al.
        Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity.
        J Clin Invest. 2000; 105: R15-R24
        • Munoz R.
        • Man S.
        • Shaked Y.
        • Lee C.R.
        • Wong J.
        • Francia G.
        • et al.
        Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy.
        Cancer Res. 2006; 66: 3386-3391
        • Allegrini G.
        • Di Desidero T.
        • Barletta M.T.
        • Fioravanti A.
        • Orlandi P.
        • Canu B.
        • et al.
        Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers.
        Angiogenesis. 2012; 15: 275-286
        • Eisenhauer E.A.
        • Therasse P.
        • Bogaerts J.
        • Schwartz L.H.
        • Sargent D.
        • Ford R.
        • et al.
        New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
        Eur J Cancer. 2009; 45: 228-247
      3. Common terminology criteria for adverse events : (CTCAE)/. v4.03. U.S. Department of Health and Human Services, Bethesda, Md2010
        • Fumagalli D.
        • Gavin P.G.
        • Taniyama Y.
        • Kim S.-I.
        • Choi H.-J.
        • Paik S.
        • et al.
        A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes.
        BMC Canc. 2010; 10: 101
        • Arcila M.
        • Lau C.
        • Nafa K.
        • Ladanyi M.
        Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping.
        J Mol Diagn. 2011; 13: 64-73
        • Aparicio T.
        • Ghiringhelli F.
        • Boige V.
        • Le Malicot K.
        • Taieb J.
        • Bouché O.
        • et al.
        Bevacizumab maintenance versus No maintenance during chemotherapy-free intervals in metastatic colorectal cancer: a randomized phase III trial (PRODIGE 9).
        J Clin Oncol. 2018; 36: 674-681
        • Cremolini C.
        • Antoniotti C.
        • Lonardi S.
        • Rossini D.
        • Pietrantonio F.
        • Cordio S.S.
        • et al.
        LBA20TRIBE2: a phase III, randomized strategy study by GONO in the 1st- and 2nd-line treatment of unresectable metastatic colorectal cancer (mCRC) patients (pts).
        Ann Oncol. 2018; 29